Gonadotrophin-releasing hormone agonists for fertility preservation: Unraveling the enigma?

Human Reproduction

Volumn 30, Issue 5, 2015, Pages 1089-1101

  Hasky, Noa ^a   Uri Belapolsky, Shiri ^a   Goldberg, Keren ^a   Miller, Irit ^a   Grossman, Hadas ^a   Stemmer, Salomon M ^a   Ben Aharon, Irit ^a   Shalgi, Ruth ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

AMH; cyclophosphamide; doxorubicin; GnRH a; VEGF

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LEUPRORELIN; MUELLERIAN INHIBITING FACTOR; SODIUM CHLORIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; GONADORELIN; GONADORELIN RECEPTOR; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FERTILITY PRESERVATION; GRANULOSA CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY DISEASE; PROTEIN EXPRESSION; RAT; RNA EXTRACTION; TUNEL ASSAY; AGONISTS; ANIMAL; CHEMISTRY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; LONGITUDINAL STUDY; METABOLISM; OVARY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROCEDURES; WISTAR RAT;

MUS; RATTUS;

ANIMALS; ANTI-MULLERIAN HORMONE; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; APOPTOSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDIES; MICE; MICE, INBRED ICR; OVARY; PHOSPHORYLATION; RATS; RATS, WISTAR; RECEPTORS, LHRH; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84929729039     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dev037     Document Type: Article

References (62)

1. Adhikari D, Liu K. Molecular mechanisms underlying the activation of mammalian primordial follicles. Endocr Rev 2009;30:438-464.
2. Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, Lyons P, Behera M, Copland S, Kimmick G et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 26:286-295.
3. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-Term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011;96:1336-1343.
4. Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ.Aluteinizing hormone-releasing hormone agonist for the prevention of chemotherapyinduced ovarian follicular loss in rats. Cancer Res 1985;45:3651-3656.
5. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-372.
6. Bar-Joseph H, Ben-Aharon I, Rizel S, Stemmer SM, Tzabari M, Shalgi R. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol 2010;30:566-572.
7. Bar-Joseph H, Ben-Aharon I, Tzabari M, Tsarfaty G, Stemmer SM, Shalgi R. In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One 2011;6:e23492.
8. Beck-Fruchter R, Weiss A, Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 2008;14:553-561.
9. Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, Stemmer SM, Shalgi R. Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol 2010;8:20.
10. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-Analysis. Breast Cancer Res Treat 2010; 122:803-811.
11. Blumenfeld Z, Dann E. GnRH agonist for the prevention of chemotherapyinduced ovarian failure in lymphoma. J Clin Oncol 2013;31:3721.
12. Blumenfeld Z, von Wolff M. GnRH-Analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008;14:543-552.
13. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamideinduced gonadotoxicity in female rats. Br J Cancer 1990;61:861-865.
14. Broer SL, Eijkemans MJC, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP, Laven JSE, de Jong FH, Te Velde ER, Fauser BC et al. Anti-mullerian hormone predicts menopause: a long-Term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011;96:2532-2539.
15. Brougham MFH, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WHB. Anti-Mullerian hormone is a marker of gonadotoxicity in pre-And postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab 2012;97:2059-2067.
16. Brown C, LaRocca J, Pietruska J, Ota M, Anderson L, Smith SD, Weston P, Rasoulpour T, Hixon ML. Subfertility caused by altered follicular development and oocyte growth in female mice lacking PKB alpha/Akt1. Biol Reprod 2010;82:246-256.
17. Chuderland D, Ben-Ami I, Friedler S, Hasky N, Ninio-Many L, Goldberg K, Bar-Joseph H, Grossman H, Shalgi R. Hormonal regulation of pigment epithelium-derived factor (PEDF) expression in the endometrium. Mol Cell Endocrinol 2014;390:85-92.
18. Desmeules P, Devine PJ. Characterizing the ovotoxicity of cyclophosphamide metabolites on cultured mouse ovaries. Toxicol Sci 2006;90:500-509.
19. Dong M, Huang L, Wang W, Du M. Regulation of AM Hand SCF expression in human granulosa cells by GnRH agonist and antagonist. Pharmazie 2011; 66:2006-2009.
20. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999;140:5789-5796.
21. Durlinger ALL, Gruijters MJG, Kramer P, Karels B, Ingraham HA, Nachtigal MW, Uilenbroek JTJ, Grootegoed JA, Themmen APN. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002;143:1076-1084.
22. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323-327.
23. Gad SC. Animal Models in Toxicology, 2nd edn. CRC Press, 2006; Available from: http://www.crcpress.com/product/isbn/9780824754075.
24. Goto M, Iwase A, Ando H, Kurotsuchi S, Harata T, Kikkawa F. PTEN and Akt expression during growth of human ovarian follicles. J Assist Reprod Genet 2007;24:541-546.
25. Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 2007;63:102-106.
26. Jayaprakasan K, Campbell BK, Hopkisson JF, Clewes JS, Johnson IR, Raine-Fenning NJ. Effect of pituitary desensitization on the early growing follicular cohort estimated using anti-Mullerian hormone. Hum Reprod 2008;23:2577-2583.
27. Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S, Wolf I, Kanety H, Sredni B, Meirow D. Cyclophosphamide triggers follicle activation and burnout; AS101 prevents follicle loss and preserves fertility. Sci Transl Med 2013;5:185ra62.
28. Kevenaar ME, MeerasahibMF, Kramer P, van de Lang-BornBMN, de Jong FH, Groome NP, Themmen APN, Visser JA. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 2006;147:3228-3234.
29. Kishk EAF, Mohammed Ali MH. Effect of a gonadotropin-releasing hormone analogue on cyclophosphamide-induced ovarian toxicity in adult mice. Arch Gynecol Obstet 2013;287:1023-1029.
30. Kitahara K, Sakai Y, Hosaka M, Hira Y, Kakizaki H, Watanabe T. Effects of a depot formulation of theGnRHagonist leuprorelin on the ultrastructure of male rat pituitary gonadotropes. Arch Histol Cytol 2007;70:79-93.
31. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamideinduced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403-1409.
32. La Marca A, Stabile G, ArtenisioAC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle.HumReprod 2006;21:3103-3107.
33. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
34. Lee JR, Kim SH, Kim SM, Jee BC, Ku S-Y, Suh CS, Choi YM, Kim JG, Moon SY. Follicular fluid anti-Mullerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles. Fertil Steril 2008;89:860-867.
35. Lee JR, Kim SH, Kim SM, Jee BC, Ku S-Y, Suh CS, Choi YM, Kim JG, Moon SY. Anti-Mullerian hormone dynamics during controlledovarian hyperstimulation and optimal timing of measurement for outcome prediction. Hum Reprod 2010;25:2597-2604.
36. Letterie GS. Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure. Hum Reprod 2004;19:831-837.
37. Li X, Kang X, Deng Q, Cai J, Wang Z.Combination of aGnRHagonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study. Reprod Biol Endocrinol 2013;11:16.
38. Lin Q, Wang Y, Weng H, Sheng X, Jiang Q, Yang Z. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice. J Zhejiang Univ Sci B 2012;13:894-903.
39. Litichever N, Gershon E, Dekel N, Koch Y. Hormonal regulation of GnRH and LHbeta mRNA expression in cultured rat granulosa cells. J Mol Neurosci 2009;39:78-85.
40. MarcelloMF, Nuciforo G, RomeoR, Di Dino G, Russo I, Russo A, Palumbo G, Schiliro G. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment. Cancer 1990;66:2099-2104.
41. Matsuo G, Ushijima K, Shinagawa A, Takahashi S-I, Fujiyoshi N, Takemoto S, Terada A, Fukui A, Kamura T. GnRH agonist acts as ovarian protection in chemotherapy induced gonadotoxicity: an experiment using a rat model. Kurume Med J 2007;54:25-29.
42. MeirowD, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 1999; 14:1903-1907.
43. Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, Raanani H, Levron J, Fridman E. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod 2007;22:1626-1633.
44. Morgan S, Lopes F, Gourley C, Anderson RA, Spears N. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PLoS One 2013; 8:e70117.
45. Ninio-Many L, Grossman H, Levi M, Zilber S, Tsarfaty I, Shomron N, Tuvar A, Chuderland D, Stemmer SM, Ben-Aharon I et al. MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience 2014;1:250-261.
46. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110: 2222-2229.
47. Orly J, Sato G, Erickson GF. Serum suppresses the expression of hormonally induced functions in cultured granulosa cells. Cell 1980;20:817-827.
48. Ozcelik B, Turkyilmaz C, Ozgun MT, Serin IS, Batukan C, Ozdamar S, Ozturk A. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertil Steril 2010;93: 1609-1614.
49. Parborell F, Pecci A, Gonzalez O, Vitale A, Tesone M. Effects of a gonadotropin-releasing hormone agonist on rat ovarian follicle apoptosis: regulation by epidermal growth factor and the expression of Bcl-2-related genes. Biol Reprod 2002;67:481-486.
50. Parborell F, Irusta G, Rodriguez Celin A, Tesone M. Regulation of ovarian angiogenesis and apoptosis by GnRH-I analogs. Mol Reprod Dev 2008; 75:623-631.
51. PartridgeAH, RuddyKJ, Gelber S, Schapira L, AbusiefM, MeyerM, Ginsburg E. Ovarian reserve inwomenwhoremain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010;94:638-644.
52. Reddy P, Shen L, Ren C, Boman K, Lundin E, Ottander U, Lindgren P, Liu Y-X, Sun Q-Y, Liu K. Activation of Akt (PKB) and suppression of FKHRL1 in mouse and rat oocytes by stem cell factor during follicular activation and development. Dev Biol 2005;281:160-170.
53. ReddyP, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, ShenY, DuC, TangW, Hamalainen T, Peng SL et al. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 2008;319: 611-613.
54. Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY) 2011;3:782-793.
55. Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, FreemanEW, Gracia CR, DeMichele A. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-Aged breast cancer survivors. Cancer 2010;116:592-599.
56. Thomas FH, Telfer EE, Fraser HM. Expression of anti-Mullerian hormone protein during early follicular development in the primate ovary in vivo is influenced by suppression of gonadotropin secretion and inhibition of vascular endothelial growth factor. Endocrinology 2007;148:2273-2281.
57. Turner NH, Partridge A, Sanna G, Di Leo A, Biganzoli L. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol 2013.Available from: http://www.ncbi.nlm.nih.gov/pubmed/23709175.
58. Van Beek RD, van den Heuvel-Eibrink MM, Laven JSE, de Jong FH, Themmen APN, Hakvoort-Cammel FG, van den Bos C, van den Berg H, Pieters R, de Muinck Keizer-Schrama SMPF. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007; 92:3869-3874.
59. Van Rooij IAJ, Broekmans FJM, te Velde ER, Fauser BCJM, Bancsi LFJMM, de Jong FH, Themmen APN. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065-3071.
60. Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973;289:1159-1162.
61. Winkler N, Bukulmez O, Hardy DB, Carr BR. Gonadotropin releasing hormone antagonists suppress aromatase and anti-Mullerian hormone expression in human granulosa cells. Fertil Steril 2010;94:1832-1839. Elsevier Ltd.
62. Yuce MA, Balkanli Kaplan P, Gucer F, Doganay L, Altaner S, Canda T, Yardim T. Prevention of cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in mice: a dose-dependent relationship?. Eur J Gynaecol Oncol 2004;25:628-631.